ProQR Therapeutics Yönetim
Yönetim kriter kontrolleri 4/4
ProQR Therapeutics CEO'su Daniel de Boer, Feb2012 tarihinde atandı, in görev süresi 12.75 yıldır. in toplam yıllık tazminatı € 2.44M olup, şirket hissesi ve opsiyonları dahil olmak üzere 21.5% maaş ve 78.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.68% ine doğrudan sahiptir ve bu hisseler $ 2.55M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.8 yıl ve 6.2 yıldır.
Anahtar bilgiler
Daniel de Boer
İcra Kurulu Başkanı
€2.4m
Toplam tazminat
| CEO maaş yüzdesi | 21.5% |
| CEO görev süresi | 12.8yrs |
| CEO sahipliği | 0.7% |
| Yönetim ortalama görev süresi | 4.8yrs |
| Yönetim Kurulu ortalama görev süresi | 6.2yrs |
Son yönetim güncellemeleri
Recent updates
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump
Oct 23
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected
Jul 15Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher
May 29Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01
ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder
Jan 07ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Dec 28A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns
Dec 01CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -€24m |
| Jun 30 2024 | n/a | n/a | -€22m |
| Mar 31 2024 | n/a | n/a | -€27m |
| Dec 31 2023 | €2m | €524k | -€28m |
| Sep 30 2023 | n/a | n/a | -€36m |
| Jun 30 2023 | n/a | n/a | -€54m |
| Mar 31 2023 | n/a | n/a | -€59m |
| Dec 31 2022 | €2m | €504k | -€64m |
| Sep 30 2022 | n/a | n/a | -€69m |
| Jun 30 2022 | n/a | n/a | -€61m |
| Mar 31 2022 | n/a | n/a | -€63m |
| Dec 31 2021 | €2m | €449k | -€61m |
| Sep 30 2021 | n/a | n/a | -€57m |
| Jun 30 2021 | n/a | n/a | -€55m |
| Mar 31 2021 | n/a | n/a | -€43m |
| Dec 31 2020 | €3m | €449k | -€47m |
| Sep 30 2020 | n/a | n/a | -€52m |
| Jun 30 2020 | n/a | n/a | -€51m |
| Mar 31 2020 | n/a | n/a | -€58m |
| Dec 31 2019 | €2m | €449k | -€56m |
| Sep 30 2019 | n/a | n/a | -€51m |
| Jun 30 2019 | n/a | n/a | -€45m |
| Mar 31 2019 | n/a | n/a | -€40m |
| Dec 31 2018 | €1m | €445k | -€37m |
| Sep 30 2018 | n/a | n/a | -€35m |
| Jun 30 2018 | n/a | n/a | -€40m |
| Mar 31 2018 | n/a | n/a | -€44m |
| Dec 31 2017 | €1m | €353k | -€44m |
Tazminat ve Piyasa: Daniel 'ın toplam tazminatı ($USD 2.54M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.18M ).
Tazminat ve Kazançlar: Daniel 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Daniel de Boer (41 yo)
12.8yrs
Görev süresi
€2,439,000
Tazminat
Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He serves as Member of Strategic Advisory Board at Hybridize...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 12.8yrs | €2.44m | 0.68% $ 2.5m | |
| Founder & Independent Member of Supervisory Board | no data | €150.00k | 0.41% $ 1.5m | |
| Chief Corporate Development Officer | 2.4yrs | €1.31m | 0.45% $ 1.7m | |
| Co-Founder | 12.8yrs | €34.00k | Veri yok | |
| Chief Financial Officer | 2yrs | Veri yok | Veri yok | |
| Chief People & Operations Officer | 4.8yrs | Veri yok | Veri yok | |
| Vice President of Investor Relations & Corporate Communications | no data | Veri yok | Veri yok | |
| Junior Financial Controller | no data | Veri yok | Veri yok |
4.8yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş
Deneyimli Yönetim: PRQR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder & Independent Member of Supervisory Board | 10.8yrs | €150.00k | 0.41% $ 1.5m | |
| Independent Member of Supervisory Board | 10.2yrs | €126.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | 7.4yrs | Veri yok | Veri yok | |
| Supervisory Board Member | 1.5yrs | €271.00k | 0.026% $ 95.7k | |
| Chairman of the Board of Directors & Chairman of Scientific Advisory Board | 4.3yrs | €132.00k | 0.060% $ 222.2k | |
| Member of the Board of Directors | 5.8yrs | €127.00k | 0% $ 0 | |
| Supervisory Board Member & Member of Scientific Advisory Board | 4.3yrs | Veri yok | Veri yok | |
| Member Scientific Advisory Board | 6.6yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 6.5yrs | Veri yok | Veri yok | |
| Member of the Board of Directors | 1.8yrs | €84.00k | 0% $ 0 |
6.2yrs
Ortalama Görev Süresi
63.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: PRQR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.2 yıldır).